Arc Therapeutics

Arc Therapeutics is a U. S. -based biopharmaceutical company focused on innovative healthcare solutions, aiming to develop advanced treatments for a variety of health conditions using cutting-edge technology. Arc Therapeutics specializes in biopharmaceuticals, delivering innovative health solutions.

The company was formed with a strategic focus on therapeutic advancements. Their headquarters are located in the United States. Arc Therapeutics raised USD 200,000 in its most recent funding round from investor Antler, totaling USD 200,000 raised to date. The company has conducted one investment deal as of August 2025.

Arc Therapeutics specializes in biopharmaceutical developments aimed at delivering innovative treatments for various health conditions. Their core product offerings focus on advanced therapeutic solutions that address specific medical needs, enhancing patient outcomes through technology and research. The company targets a diverse client base including healthcare providers, hospitals, and research institutions, with a specific emphasis on North America and Europe. Their products cater to both chronic and acute health issues, providing effective therapeutic alternatives.

Through continuous research and development, Arc Therapeutics aims to expand its portfolio, improving accessibility to healthcare solutions globally. Arc Therapeutics operates on a transaction structure involving B2B partnerships with healthcare providers and institutions. Revenue generation occurs through the sale of proprietary therapeutic products supplied directly to hospitals and clinics, including strategic collaborations with pharmaceutical distributors. Pricing plans for flagship products align with industry standards to ensure competitive positioning in the market.

Their sales model also incorporates subscription-based access for certain services, facilitating integration into ongoing treatment programs. This approach supports consistent revenue flow while enhancing client engagement through tailored solutions. In August 2025, Arc Therapeutics raised USD 200,000 in pre-seed funding to support future growth initiatives. The company plans to launch new products aimed at addressing unmet medical needs and is actively exploring expansion into new geographic markets, particularly targeting North America and Europe by the end of 2026.

The recent funding will be utilized to support product development and market entry strategies.